• Product NameGSK461364
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityGSK461364 inhibits purified Plk1 with Ki of 2.2 nM. It is more than 1000-fold selective against Plk2/3. Phase 1.
• Target NamePLK inhibitor
• CAS No. 929095-18-1
• Calculated MW 543.6
• Formulation C27H28F3N5O2S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:C[C@@H](OC1=C(SC(=C1)N1C=NC2=C1C=C(CN1CCN(C)CC1)C=C2)C(N)=O)C1=CC=CC=C1C(F)(F)F |r,c:6,10,12,26,34,36,t:3,15,32|
  Pathways:Cell Cycle/Checkpoint
  Receptor:PLK1
  Boling pt:
  Melting pt:
  Solubility:DMSO:10 mg/mL (18.39 mM)Ethanol:30 mg/mL (55.18 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Gilmartin AG, et al. Cancer Res, 2009, 69(17), 6969-6977.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting